Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines

Experimental and Molecular Medicine

Volumn 46, Issue 3, 2014, Pages

  Kim, Sae Hae ^a   Jang, Yong Suk ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Immunity; M cell; Vaccine

Indexed keywords

ADJUVANT; ANTIGEN; BACTERIAL VACCINE; VACCINE; VIRUS VACCINE; BACTERIAL ANTIGEN; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; CELL DIFFERENTIATION; CELL LINE; CELL MATURATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; DRUG EFFICACY; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; M CELL; NONHUMAN; PROTEIN TARGETING; REVIEW; VACCINATION; ANIMAL; CYTOLOGY; IMMUNOLOGY; INTESTINE MUCOSA; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; PEYER PATCH;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; BACTERIAL VACCINES; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; PEYER'S PATCHES; VIRAL VACCINES;

EID: 84902150134     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.165     Document Type: Review

References (84)

1. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005; 5: 905-916.
2. Mestecky J, Nguyen H, Czerkinsky C, Kiyono H. Oral immunization: an update. Curr Opin Gastroenterol 2008; 24: 713-719.
3. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6: 148-158.
4. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45-S53.
5. Hoft DF, Brusic V, Sakala IG. Optimizing vaccine development. Cell Microbiol 2011; 13: 934-942.
6. Holmgren J, Svennerholm AM. Vaccines against mucosal infections. Curr Opin Immunol 2012; 24: 343-353.
7. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33: 492-503.
8. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012; 12: 592-605.
9. Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature 2011; 477: 462-465.
10. Peltola H, Siitonen A, Kyronseppa H, Simula I, Mattila L, Oksanen P et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338: 1285-1289.
11. Clemens J, Shin S, Sur D, Nair GB, Holmgren J. New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol 2011; 8: 701-710.
12. Anh DD, Lopez AL, Thiem VD, Grahek SL, Duong TN, Park JK et al. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study. PLoS Negl Trop Dis 2011; 5: e1006.
13. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004; 82: 346-353.
14. Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007; 25: 7848-7857.
15. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006; 24: 116-123.
16. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in entericcoated capsules: a field trial in an endemic area. J Infect Dis 1989; 159: 766-769.
17. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 136-141.
18. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362: 289-298.
19. Greenberg HB, Estes MK. Rotaviruses: from pathogenesis to vaccination. Gastroenterology 2009; 136: 1939-1951.
20. Brandtzaeg P, Kiyono H, Pabst R, Russell MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008; 1: 31-37.
21. Chen K, Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 2010; 33: 479-491.
22. Bemark M, Boysen P, Lycke NY. Induction of gut IgA production through T cell-dependent and T cell-independent pathways. Ann NY Acad Sci 2012; 1247: 97-116.
23. Pabst O. New concepts in the generation and functions of IgA. Nat Rev Immunol 2012; 12: 821-832.
24. Strugnell RA, Wijburg OL. The role of secretory antibodies in infection immunity. Nat Rev Microbiol 2010; 8: 656-667.
25. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169: 566-574.
26. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997; 65: 1387-1394.
27. Quiding M, Nordstrom I, Kilander A, Andersson G, Hanson LA, Holmgren J et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest 1991; 88: 143-148.
28. Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine 2012; 30: 142-154.
29. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011; 71: 1591-1622.
30. Smith DJ, Bot S, Dellamary L, Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine 2003; 21: 2805-2812.
31. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, Vimeux L et al. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 2010; 28: 5582-5590.
32. Curran RM, Donnelly L, Morrow RJ, Fraser C, Andrews G, Cranage M et al. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 2009; 27: 6791-6798.
33. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 2006; 80: 5283-5291.
34. McGowin CL, Pyles RB. Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy. Future Microbiol 2010; 5: 15-22.
35. Nesburn AB, Slanina S, Burke RL, Ghiasi H, Bahri S, Wechsler SL. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol 1998; 72: 7715-7721.
36. Azizi A, Kumar A, Diaz-Mitoma F, Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 2010; 6: e1001147.
37. van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 2009; 71: 241-260.
38. Clevers H. The intestinal crypt, a prototype stem cell compartment. Cell 2013; 154: 274-284.
39. Schulz O, Pabst O. Antigen sampling in the small intestine. Trends Immunol 2013; 34: 155-161.
40. Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol 2008; 52: 2-12.
41. Owen RL, Jones AL. Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 1974; 66: 189-203.
42. Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996; 86: 345-348.
43. Mach J, Hshieh T, Hsieh D, Grubbs N, Chervonsky A. Development of intestinal M cells. Immunol Rev 2005; 206: 177-189.
44. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-265.
45. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003-1007.
46. Gregorieff A, Stange DE, Kujala P, Begthel H, van den Born M, Korving J et al. The ets-domain transcription factor Spdef promotes maturation of goblet and paneth cells in the intestinal epithelium. Gastroenterology 2009; 137: 1333-1345.
47. de Lau W, Kujala P, Schneeberger K, Middendorp S, Li VS, Barker N et al. Peyer's patch M cells derived from Lgr5(+) stem cells require SpiB and are induced by RankL in cultured 'miniguts'. Mol Cell Biol 2012; 32: 3639-3647.
48. Mabbott NA, Donaldson DS, Ohno H, Williams IR, Mahajan A. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol 2013; 6: 666-677.
49. Hsieh EH, Lo DD. Jagged1 and Notch1 help edit M cell patterning in Peyer's patch follicle epithelium. Dev Comp Immunol 2012; 37: 306-312.
50. Sato S, Kaneto S, Shibata N, Takahashi Y, Okura H, Yuki Y et al. Transcription factor Spi-B-dependent and-independent pathways for the development of Peyer's patch M cells. Mucosal Immunol 2013; 6: 838-846.
51. Tahoun A, Mahajan S, Paxton E, Malterer G, Donaldson DS, Wang D et al. Salmonella transforms follicle-associated epithelial cells into M cells to promote intestinal invasion. Cell Host Microbe 2012; 12: 645-656.
52. Kanaya T, Hase K, Takahashi D, Fukuda S, Hoshino K, Sasaki I et al. The Ets transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. Nat Immunol 2012; 13: 729-736.
53. Kuolee R, Chen W. M cell-targeted delivery of vaccines and therapeutics. Expert Opin Drug Deliv 2008; 5: 693-702.
54. Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 2007; 204: 2789-2796.
55. Kerneis S, Bogdanova A, Kraehenbuhl JP, Pringault E. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 1997; 277: 949-952.
56. Foster N, Clark MA, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 1998; 16: 536-541.
57. Clark MA, Jepson MA, Simmons NL, Hirst BH. Differential surface characteristics of M cells from mouse intestinal Peyer's and caecal patches. Histochem J 1994; 26: 271-280.
58. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572: 232-254.
59. Kim SH, Jung DI, Yang IY, Kim J, Lee KY, Nochi T et al. M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery. Eur J Immunol 2011; 41: 3219-3229.
60. Kunisawa J, Kurashima Y, Kiyono H. Gut-associated lymphoid tissues for the development of oral vaccines. Adv Drug Deliv Rev 2012; 64: 523-530.
61. Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009; 462: 226-230.
62. Wolf JL, Kauffman RS, Finberg R, Dambrauskas R, Fields BN, Trier JS. Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. Gastroenterology 1983; 85: 291-300.
63. Clark MA, Hirst BH, Jepson MA. M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells. Infect Immun 1998; 66: 1237-1243.
64. Keely S, Glover LE, Weissmueller T, MacManus CF, Fillon S, Fennimore B et al. Hypoxia-inducible factor-dependent regulation of platelet-activating factor receptor as a route for gram-positive bacterial translocation across epithelia. Mol Biol Cell 2010; 21: 538-546.
65. Shafique M, Wilschut J, de Haan A. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 2012; 30: 597-606.
66. Tyrer P, Foxwell AR, Cripps AW, Apicella MA, Kyd JM. Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect Immun 2006; 74: 625-631.
67. Nakato G, Hase K, Suzuki M, Kimura M, Ato M, Hanazato M et al. Cutting Edge: Brucella abortus exploits a cellular prion protein on intestinal M cells as an invasive receptor. J Immunol 2012; 189: 1540-1544.
68. Rand JH, Wu XX, Lin EY, Griffel A, Gialanella P, McKitrick JC. Annexin A5 binds to lipopolysaccharide and reduces its endotoxin activity. MBio 2012; 3: e00292-11.
69. Osanai A, Sashinami H, Asano K, Li SJ, Hu DL, Nakane A. Mouse peptidoglycan recognition protein PGLYRP-1 plays a role in the host innate immune response against Listeria monocytogenes infection. Infect Immun 2011; 79: 858-866.
70. Kyd JM, Cripps AW. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine 2008; 26: 6221-6224.
71. Lo DD, Ling J, Eckelhoefer AH. M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses. BMC Biotechnol 2012; 12: 7.
72. Kim SH, Seo KW, Kim J, Lee KY, Jang YS. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J Immunol 2010; 185: 5787-5795.
73. Kobayashi A, Donaldson DS, Kanaya T, Fukuda S, Baillie JK, Freeman TC et al. Identification of novel genes selectively expressed in the follicle-associated epithelium from the meta-analysis of transcriptomics data from multiple mouse cell and tissue populations. DNA Res 2012; 19: 407-422.
74. Nakato G, Fukuda S, Hase K, Goitsuka R, Cooper MD, Ohno H. New approach for m-cell-specific molecules screening by comprehensive transcriptome analysis. DNA Res 2009; 16: 227-235.
75. Kim SH, Lee KY, Jang YS. Mucosal immune system and M cell-targeting strategies for oral mucosal vaccination. Immune Netw 2012; 12: 165-175.
76. Tsuji NM, Kosaka A. Oral tolerance: intestinal homeostasis and antigenspecific regulatory T cells. Trends Immunol 2008; 29: 532-540.
77. Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol 2012; 5: 232-239.
78. Manicassamy S, Pulendran B. Modulation of adaptive immunity with Tolllike receptors. Semin Immunol 2009; 21: 185-193.
79. Uematsu S, Fujimoto K, Jang MH, Yang BG, Jung YJ, Nishiyama M et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 2008; 9: 769-776.
80. Agren LC, Ekman L, Lowenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997; 158: 3936-3946.
81. Eliasson DG, Helgeby A, Schon K, Nygren C, El-Bakkouri K, Fiers W et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 2011; 29: 3951-3961.
82. Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 2009; 19: 2-11.
83. Avalos AM, Busconi L, Marshak-Rothstein A. Regulation of autoreactive B cell responses to endogenous TLR ligands. Autoimmunity 2010; 43: 76-83.
84. Sebert P, Barthelemy L, Dietman Y, Douguet C, Boulay J. A simple device for measuring a vertical jump: description and results. Eur J Appl Physiol Occup Physiol 1990; 61: 271-273.